Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 13/20 | 0.55 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29174216 | 0.89 | OPRM1 (0.66) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL8636898 | 0.87 | OPRM1 (0.50) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL6045629 | 0.85 | OPRM1 (0.60) | OPRM1OPRD1OPRK1CACNA1CSLC22A1 | |
| Oxalic Acid SCHEMBL6045761 | 0.82 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CACNA1C | |
| Oxalic Acid SCHEMBL6045561 | 0.80 | OPRM1 (0.83) | OPRM1OPRD1OPRK1CACNA1C | |
| Oxalic Acid SCHEMBL11563217 | 0.79 | OPRM1 (0.81) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL6045500 | 0.79 | OPRM1 (0.69) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL6045502 | 0.79 | OPRM1 (0.61) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL6963041 | 0.79 | OPRM1 (0.44) | OPRM1OPRD1OPRK1CACNA1C | |
| Oxalic Acid SCHEMBL6045559 | 0.78 | OPRM1 (0.56) | OPRM1OPRD1OPRK1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | OPRM1 148/4885SLC6A4 834/4885OPRD1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.